AI Earnings Predictions for MaxCyte Inc. (MXCT)

EX-99.1

2 mxct-20260512xex99d1.htm

EX-99.1

​

Exhibit 99.1

​

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

​

First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue

Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million

MaxCyte’s Board authorized a $10 million share repurchase program

ROCKVILLE, MD, May 12, 2026 — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2026 financial results and reiterated its 2026 guidance.

​

“We are pleased with our performance in the first quarter, and remain confident in our full year guidance,” said Maher Masoud, President and CEO of MaxCyte.  “Our core revenue from partners and customers was in line with our expectations for both our ExPERT electroporation platforms and SeQure services. The SPL portfolio continues to advance in the clinic, including a clinical customer that began dosing patients in a registrational study in the first quarter, and we remain confident additional customers will initiate registrational trials this year. Further, our SPL portfolio remains strong and spans a broad range of modalities and indications. MaxCyte remains extremely well positioned in the cell & gene therapy industry, with leading technology and an efficient cost structure. Reflecting continued confidence in our strategy and the long-term value of our business, the Board today authorized a $10 million share repurchase. This authorization provides us with flexibility in capital allocation while we continue to invest in key growth initiatives, including the recent launch of ExPERT DTx and the integration of SeQure Dx. We believe this balanced approach enables us to both reinvest in the business and return capital to shareholders.”

​

First Quarter Financial Results

·

Total revenue of $9.7 million in the first quarter of 2026, a decrease of 7% over the first quarter of 2025.

o

Core business revenue of $6.2 million in the first quarter of 2026, a decrease of 25% over the first quarter of 2025.

o

Strategic Platform License (SPL) Program-related revenue was $3.4 million for the first

o

quarter of 2026, compared to $2.1 million in the first quarter of 2025.

·

Gross profit for the first quarter of 2026 was $8.1 million (84% gross margin), compared to $8.9 million (86% gross margin) in the first quarter of 2025.

·

Non-GAAP adjusted gross margin was 78% when excluding SPL Program-related revenue and reserves for excess and obsolete inventory, compared to non-GAAP adjusted gross margin of 83% in the first quarter of 2025.

·

Operating expenses for the first quarter of 2026 were $14.3 million, compared to operating expenses of $21.2 million in the first quarter of 2025.

​

1

​

·

First quarter 2026 net loss was $4.8 million compared to net loss of $10.3 million for the same period in 2025.

·

EBITDA, a non-GAAP measure, was a loss of $5.1 million for the first quarter of 2026, compared to a loss of $11.2 million for the first quarter of 2025; stock-based compensation expense was $1.1 million in the first quarter of 2026 compared to $3.0 million in the first quarter of 2025.

·

Total SPL agreements was 29 as of March 31, 2026, which includes 12 programs currently in the clinic (defined as programs with at least a cleared IND or equivalent) and one commercial program.

·

Total cash, cash equivalents and investments were $147.7 million as of March 31, 2026.

​

Full Year 2026 Guidance

·

Full year revenue expected to be $30 million to $32 million consisting of:

o

Core revenue of $25 million to $27 million.

o

SPL Program-related revenue of approximately $5 million for the year; SPL Program-related revenue guidance includes both revenue of approximately $3 million from milestone payments and approximately $2 million from commercial royalties.

·

MaxCyte expects to end 2026 with at least $136 million in total cash, cash equivalents and investments, which does not include capital to be used for the share repurchase program.

The following tables provide details regarding the sources of our revenue for the periods presented.

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

​

​

March 31

​

​

​

​

​

(Unaudited)

​

​

​

​

​ ​ ​

2026

​ ​ ​

2025

​ ​ ​

%

​

(in thousands, except percentages)

​

​

​

​

​

​

​

​

​

Instruments

​

$

1,346

​

$

1,444

​

(7%)

​

PAs and consumables

​

​

2,293

​

​

3,871

​

(41%)

​

Licenses

​

​

2,097

​

​

2,531

​

(17%)

​

Assay service

​

​

188

​

​

142

​

32

%

Other

​

​

294

​

​

255

​

15

%

Total Core Revenue

​

$

6,218

​

$

8,243

​

(25%

EX-99.1

2 mxct-20260324xex99d1.htm

EX-99.1

​

Exhibit 99.1

​

​

​

​

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

​

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement

Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement

Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in total cash, cash equivalents and investments

Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million

ROCKVILLE, MD, March 24, 2026 — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its fourth quarter and full year ended December 31, 2025 financial results and initiated its 2026 guidance.

“Our 2025 revenues were impacted by headwinds from select SPL customers, including a 15% reduction in purchases and leases from our largest customer, which we expect to stabilize in the second half of 2026 and grow from that new base. Despite these near-term challenges, we made meaningful progress in 2025: reducing annual cash burn by more than $16 million, streamlining our cost structure, and advancing new product launches, all which we believe will strengthen MaxCyte's position in the growing cell and gene therapy market for the long term,” said Maher Masoud, President and CEO of MaxCyte.

“We also continued to expand our SPL portfolio, by signing 4 new SPLs in 2025.   As we look ahead to 2026, we will focus on growing our sales pipeline across our ExPERT electroporation platform and SeQure assay services business units, including driving growth in our new ExPERT DTx discovery platform which launched last month. Our 2026 total revenue guidance calls for $30-32 million, which we believe is appropriate as it includes approximately $4 million in core revenue headwind from select SPL customers, which began to impact revenue in the second half of 2025. I remain more excited than ever in the future growth of our company. I believe we now will be supporting up to four therapies in Phase III by the end of 2026 and have already received a milestone payment for one of these therapies. The expansion of CGT, including ongoing clinical progress, which we are part of, underpins the long-term opportunity for MaxCyte,” he added

Fourth Quarter and Full Year Highlights

●Total revenue of $7.3 million in the fourth quarter of 2025, a decrease of 16% over the fourth quarter of 2024.

oCore business revenue of $6.8 million in the fourth quarter of 2025, a decrease of 22% over the fourth quarter of 2024.

​

1

​

oStrategic Platform License (SPL) Program-related revenue was $0.5 million for the fourth quarter of 2025, compared to $0.1 million in the fourth quarter of 2024.

●Total revenue of $33.0 million for the full year 2025, a decrease of 15% over the full year 2024.

oCore business revenue of $29.6 million for the full year 2025, a decrease of 9% over the full year 2024.

oSPL Program-related revenue was $3.4 million for the full year 2025, compared to $6.1 million in full year 2024.

●Ended the year with 32 SPL agreements that include 13 programs currently in the clinic (defined as programs with at least a cleared IND or equivalent) and one commercial program.

●Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025.

​

The following tables provide details regarding the sources of our revenue for the periods presented.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​ ​ ​

Three Months Ended

​ ​ ​

Year Ended

​

​

December 31,

​

December 31,

​

​ ​ ​

2025

​ ​ ​

2024

​ ​ ​

%

​ ​ ​

2025

​ ​ ​

2024

​ ​ ​

%

​

​

​

(Unaudited)

​

​

​

(Unaudited)

​

​

​

​

​

(in thousands, except percentages)

​

​

​

​

​

​

​

​

​

​

​

​

​

Instrument

​

$

1,841

​

$

1,629

​

13

%

$

6,802

​

$

7,083

​

(4%)

​

PAs and consumables

​

​

2,312

​

​

4,169

​

(45%)

​

​

11,889

​

​

14,006

​

(15%)

​

Licenses

​

​

1,993

​

​

2,554

​

(22%)

​

​

8,946

​

​

10,297

​

(13%)

​

Assay Services

​

​

335

​

​

—

​

—

​

​

776

​

​

—

​

—

​

Other

​

​

274

​

​

258

​

6

%

​

1,190

​

​

1,126

​

6

%

Total Core Revenue

​

$

6,755

​

$

8,610

​

(22%)

​

$

29,603

​

$

32,512

​

(9%)

​

Milestones

​

​

4

​

​

4

​

0

%

​

2,265

​

​

6,015

​

(62%)

​

Royalties

​

​

541

​

​

79

​

586

%

​

1,158

​

​

100

​

(44%)

​

Total Revenue

​

$

7,300

​

$

8,693

​

(16%)

​

$

33,026

​

$

38,627

​

(15%)

​

​

In addition to revenue, management regularly reviews key business metrics to evaluate our business, measure

MaxCyte, Inc._January 12, 2026 0001287098false00012870982026-01-122026-01-12 ​ ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549 ​

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ​ Date of Report (Date of earliest event reported): January 12, 2026 ​

​ MaxCyte, Inc. (Exact name of registrant as specified in its charter) ​ ​

​

​

​

​

Delaware ​ ​ ​ 001-40674 ​ ​ ​ 52-2210438

(State or other jurisdiction of incorporation) ​ (Commission File Number) ​ (IRS Employer Identification No.)

​ 9713 Key West Avenue, Suite 400 Rockville, Maryland 20850 (Address of principal executive offices, including zip code) ​ (301) 944-1700 (Registrant’s telephone number, including area code) ​ N/A (Former name or former address, if changed since last report) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ​ ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of each class ​ ​ ​ Trading Symbol(s) ​ ​ ​ Name of each exchange on which registered

Common Stock, $0.01 par value ​

MXCT

​ The Nasdaq Stock Market LLC

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company    ☒ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​

Item 2.02. Results of Operations and Financial Condition. ​ On January 12, 2026, MaxCyte, Inc. (the “Company”) issued a press release announcing preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2025. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. ​ In accordance with General Instructions B.2. of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing. ​ Item 9.01. Financial Statements and Exhibits. ​ (d) Exhibits ​ Exhibit Number ​ ​ ​ Exhibit Description

​ ​ ​

99.1 ​ Press Release, dated January 12, 2026

104 ​ Cover Page Interactive Data (embedded within the Inline XBRL document)

​ ​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

​ MaxCyte, Inc.

​ ​

Dated: January 12, 2026 By: /s/ Douglas Swirsky

​ ​ Douglas Swirsky

​ ​ Chief Financial Officer

​ ​ ​